PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 7, 2005--The Medicines Company (NASDAQ: MDCO) today announced completion of patient enrollment in the 13,800 patient global Phase III ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. This randomized clinical trial is evaluating the direct thrombin inhibitor Angiomax(R) (bivalirudin) replacing heparins (unfractionated heparin or enoxaparin) in patients with acute coronary syndromes (ACS) presenting to the emergency department. ACUITY is being conducted at 450 clinical trial sites in 17 countries worldwide. In Europe, where more than 4,000 patients were enrolled, Nycomed is co-sponsoring the trial.
